Geovax Labs, Inc. ( (GOVX) ) has released its Q4 earnings. Here is a breakdown of the information Geovax Labs, Inc. presented to its investors.
GeoVax Labs, Inc. is a clinical-stage biotechnology company focused on developing vaccines and immunotherapies for infectious diseases and cancers. In its latest earnings report, GeoVax highlighted significant progress in its clinical trials and operational developments for the year ending December 31, 2024. The company received a $400 million award from BARDA for its GEO-CM04S1 COVID-19 vaccine, which is advancing into a Phase 2b trial. GeoVax also reported promising data from its Phase 2 trials, including positive immune response results for its COVID-19 booster vaccine in healthy adults. Additionally, the company is preparing for a Phase 2 trial of its Gedeptin therapy for head and neck cancer and is advancing its GEO-MVA vaccine platform for Mpox and Smallpox. Financially, GeoVax reported a net loss of $25 million for 2024, with revenues of $4 million from government contracts. Looking ahead, GeoVax remains focused on expanding its clinical programs and manufacturing capabilities, with an optimistic outlook for 2025.